Background: Mild head trauma often leads to long-term cognitive and neurological deficits. PLX3397, an inhibitor of colony-stimulating factor 1 receptor (CSF1R), offers promise as a therapeutic agent for traumatic brain injury (TBI) by targeting neuro-inflammation. Stem cell-based approaches are widely studied for neurological disorders. The objective of this study was to investigate therapeutic effect of intranasal administration of human neural crest-derived nasal turbinate stem cells (hNTSCs) on mild TBI in comparison with that of PLX3397.
Methods: We developed a model of mice with repetitive and mild TBI following a weight-drop once a day for 5 days. PLX3397 (50 mg/kg, p. o.) was administered for 21 days. Intranasal administration of hNTSCs (1 × 10) was performed once.
Results: Iba1 + and GFAP + cells were increased in the cortex and hippocampus of TBI models. Iba1 + cells and GFAP + cells were remarkably decreased in PLX3397 or hNTSC-treated TBI models. Administration of PLX3397 attenuated the decrease in neurobehavioral activity. Similar effects were observed in a TBI model with a single dose of hNTSC.
Conclusion: Intranasal administration of hNTSCs had a microglia-depleting effect. Administered hNTSCs were found around the cortex and hippocampus of TBI brains. This investigation may provide a promising path for therapeutic initiatives for repetitive and mild TBI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s13770-025-00702-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mesenchymal stem cell-derived extracellular vesicles alleviate autism by regulating microglial glucose metabolism reprogramming and neuroinflammation through PD-1/PD-L1 interaction.
J Nanobiotechnology
March 2025
Department of Children's and Adolescent Health, Public Health College, Harbin Medical University, Harbin, 150081, China.
Neuroinflammation triggered by microglia activation is hallmark of autism spectrum disorder (ASD), and this process includes crucial metabolic reprogramming from oxidative phosphorylation to glycolysis, which may cause neuron loss and functional impairment. The inhibitory immune checkpoint programmed cell death protein 1 (PD-1) on immune cells is an important target for tumor immunotherapy. However, the immunomodulatory effects of PD-1 in ASD remains to be elusive.
View Article and Find Full Text PDFComparison Between Etorphine-Xylazine with or Without Butorphanol and Butorphanol-Azaperone-Medetomidine For the Anesthesia of Free-Ranging Musk Ox ().
J Zoo Wildl Med
March 2025
Centre québécois sur la santé des animaux sauvages/Canadian Wildlife Health Cooperative, Faculté de médecine vétérinaire, Université de Montréal, St. Hyacinthe, Québec J2S 2M2, Canada,
Historically, free-ranging musk oxen () were anesthetized with potent opioids such as etorphine, which are often associated with marked respiratory depression. The goal of this study was to investigate alternatives to the etorphine-xylazine combination (EtXy) traditionally used in this species. First, the potential benefit of postinduction butorphanol administrations to musk oxen anesthetized with EtXy was assessed.
View Article and Find Full Text PDFThe efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature.
J Headache Pain
March 2025
Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Jiangsu Province, 188 Shizi Street, Suzhou, 215006, China.
Background: The latest randomized controlled trial (RCT) revealed that zavegepant, a new nasal inhalation calcitonin gene-related peptide (CGRP) receptor antagonist, has a clear efficacy in the acute treatment of migraine. However, whether the efficacy of this new nasal inhalation drug is better than other oral CGRP receptor antagonists remained to be confirmed. Therefore, we designed this network meta-analysis (NMA) to provide a reference for the clinical application of zavegepant.
View Article and Find Full Text PDFIntranasal Delivery of Hydrophobic AC5216 Loaded Nanoemulsion into Brain To Alleviate Chronic Unpredictable Stress-Induced Depressive-like Behaviors.
ACS Appl Mater Interfaces
March 2025
Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, Basic Medicine Research and Innovation Center of Ministry of Education, Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing 210009, China.
Major depressive disorder (MDD) represents a widespread mental health condition. Efficiently moving therapeutic substances across the blood-brain barrier (BBB) remains a critical obstacle in addressing depressive disorders. AC5216, identified as a translocator protein (TSPO) ligand and considered a potential treatment for major depressive disorder (MDD), faces limitations due to its subpar druggability and oral bioavailability.
View Article and Find Full Text PDFIntranasal Administration of Bivalent RBD Nanoparticles Elicits Strong Systemic Responses That Effectively Block Distal Dissemination of COVID-19.
Microbiol Immunol
March 2025
Department of Clinical Pathology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
The intranasal vaccine against coronavirus disease 2019 (COVID-19) has gained more attention because of its ability to induce both mucosal and systemic immune responses. We have recently developed a c-GAMP-adjuvanted bivalent receptor-binding domain (RBD) vaccine, derived from the ancestral strain and the Omicron variant. We demonstrated here that intranasal administration of this vaccine candidate triggers not only the respiratory but also the systemic immune response against SARS-CoV-2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!